Parabilis Medicines - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeParabilis Medicines
Parabilis Medicines logo

Parabilis Medicines

0 followers

About Parabilis Medicines

Parabilis Medicines is a biopharmaceutical company focused on developing ultra-tunable peptide therapeutics to address cancer and other diseases with high unmet need. The company emphasizes a research-driven approach, aiming to deploy a novel modality to achieve transformative patient outcomes. Its communications highlight a strategic focus on innovation and science-driven programs, including clinical exploration of its medicines. While the exact geographic headquarters aren’t stated in the available content, Parabilis presents itself as a dedicated biotech entity advancing next-generation peptide medicines.

Recent News

Recent Deals

Key Team Members

William Bleker, M.D.

Vice President, Clinical Safety & Pharmacovigilance

John McGee, Ph.D.

Scientific Co-Founder and Senior Vice President, Platform Technology

Greg Miller

Chief Business Officer

Richa Poddar

Senior Vice President, Commercial Strategy & Medical Affairs

Rohin Mhatre, Ph.D.

Chief Technical Operations Officer

Key Facts

HQ Location

Cambridge, United States

Founded

2016

Employees

51 - 200

Status

Private

Website

https://parabilismed.com